Skip to main content
x

Recent articles

ASH 2024 preview – best of the rest

Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.

The month ahead: December’s upcoming events

Party season approaches; but first, conferences.

Nerviano becomes a targeted PARP player

Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.

Roche doubles down on Poseida

A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.

Truqap could fill a prostate cancer gap

The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.

Targeted lung cancer niche sees a German pharma battle

But could toxicity be holding back filing plans?